{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ibanez L"],"funding":["Defense Advanced Research Projects Agency","NIA NIH HHS","Alzheimer's Association Zenith Fellows Award","Michael J. Fox Foundation for Parkinson's Research","Alzheimer's Drug Discovery Foundation","BrightFocus Foundation","National Institutes of Health","Chan Zuckerberg Initiative","Anonymous foundation","Alzheimer&apos;s Drug Discovery Foundation","Zenith Fellows Award","NIH HHS","Michael J. Fox Foundation for Parkinson&apos;s Research"],"pagination":["e14413"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11848383"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(2)"],"pubmed_abstract":["<h4>Introduction</h4>In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.<h4>Methods</h4>We compared AD-relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma.<h4>Results</h4>CSF measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p-tau217 performance is similar to that report"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pubmed_title":["Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research."],"pmcid":["PMC11848383"],"funding_grant_id":["U01AG058922","ZEN-22-848604","RF1AG058501","RF1AG083744","R01AG044546","RF1 AG074007","RF1AG053303","K99/R00-AG062723","R01AG070941","RF1 AG058501","W81XWH2010849","RF1 AG053303","K99/R00‐AG062723","R01 AG070941","R01 AG044546","RF1AG074007","P30 AG066444","P01AG003991","U01 AG058922","K99 AG062723","P01 AG026276","R00 AG062723","RF1 AG083744","P01 AG003991"],"pubmed_authors":["Lowery J","Timsina J","Liu M","Sanchez-Montejo B","Beric A","Holtzman DM","Bateman RJ","Budde JP","Moulder K","Morris JC","Brock W","Schindler SE","Cruchaga C","Kohlfeld P","Bergmann K","Barthelemy N","Xiong C","Ibanez L","Sykora N","Benzinger TLS","Tarawneh R","Sung YJ"],"additional_accession":[]},"is_claimable":false,"name":"Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research.","description":"<h4>Introduction</h4>In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.<h4>Methods</h4>We compared AD-relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma.<h4>Results</h4>CSF measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p-tau217 performance is similar to that report","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-03T23:48:05.096Z","creation":"2025-04-03T23:48:05.096Z"},"accession":"S-EPMC11848383","cross_references":{"pubmed":["39575871"],"doi":["10.1002/alz.14413"]}}